News & Views
GPCR Biosensors receive RSRI Award
Jan 17 2020 Read 405 Times
Biopharmaceutical company Domain Therapeuticsa developer of drug candidates targeting G Protein-Coupled Receptors (GPCR) in neurology, oncology and rare diseases, has received, together with Pr Michel Bouvier, the RSRI award from the Association des Directeurs de Recherche Industrielle du Quebec (ADRIQ) at the Innovation Prize gala.
Created in 2019, this award, presented by the nine Regroupement Sectoriel de Recherche Industrielle in Quebec (RSRIs), illustrates the strength of the bonds between the research community and industry. It also highlights the significant impact of a collaborative research project on the Quebec economy through the creation of new jobs.
The technology, in-licensed by Domain Therapeutics in 2013 from University of Montreal, benefited from a €1.8M (US$2M) investment from the Consortium Québécois sur la Découverte Du Médicament (CQDM) over three years and the expertise of a consortium of Canadian researchers: Pr Michel Bouvier and Dr Christian Le Gouill (IRIC – Institute for Research in Immunology and Cancer at the University of Montreal), Pr Graciela Pineyro (research center, Sainte-Justine Hospital), Pr Stéphane Laporte and Pr Terry Hebert (McGill University), and Pr Richard Leduc (Sherbrooke University).
Developing the potential uses of this technology through its Montreal based-subsidiary Domain Therapeutics NA Inc. (DTNA), the company designs biosensors for GPCR-acting treatments and applications to other membrane receptors.
“We are honoured to be awarded this prize, recognising the successful collaboration between our company and the consortium led by Pr Michel Bouvier,” said Pascal Neuville, CEO, Domain Therapeutics. “This prize highlights the quality of research in Quebec and particularly in Montreal. Domain Therapeutics is very pleased to have turned such groundbreaking innovation into a value-creation business.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Issue Articles - Review of China market shows real potential for lab companies - Biphenyl Modified Silica Stabilised by Bulky Substituents Laboratory Products - ChIP Kits for H...
View all digital editions
Sep 20 2020 Preveza, Greece
Sep 21 2020 Budapest, Hungary
Sep 22 2020 Moscow, Russia
Sep 29 2020 Utrecht, Holland
Oct 06 2020 Lagos, Nigeria